Commonwealth Coat of Arms of Australia

National Health (Continued Dispensing) Determination 2022

PB 59 of 2022

made under subsection 89A(3) of the

National Health Act 1953

Compilation No. 13

Compilation date: 1 November 2025

Includes amendments: F2025L01317

About this compilation

This compilation

This is a compilation of the National Health (Continued Dispensing) Determination 2022 that shows the text of the law as amended and in force on 1 November 2025 (the compilation date).

The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au).

Application, saving and transitional provisions

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Presentational changes

The Legislation Act 2003 provides for First Parliamentary Counsel to make presentational changes to a compilation. Presentational changes are applied to give a more consistent look and feel to legislation published on the Register, and enable the user to more easily navigate those documents.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. Any modifications affecting the law are accessible on the Register.

Selfrepealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

 

 

 

Part 1—Preliminary

1.01 Name

1.03 Authority

1.05 Definitions

1.06 Purpose

Part 2—Pharmaceutical benefits that may be supplied without a prescription

2.01 Pharmaceutical benefits covered by this instrument

Part 3—Specified conditions for supplying pharmaceutical benefits without a prescription

3.01 General

3.02 Condition—unable to obtain prescription

3.03 Condition—previous supply of pharmaceutical benefit

3.04 Condition—stability of therapy

3.05 Condition—prior clinical review by PBS prescriber

3.06 Condition—prescription for last supply of pharmaceutical benefit

3.07 Condition—no continued dispensing in previous 12 months

3.08 Condition—declaration for supply of pharmaceutical benefit

3.09 Condition—maximum quantity of supply

3.10 Condition—preparing and recording information

Schedule 1—Pharmaceutical benefits that may be supplied without a prescription pharmaceutical benefits that have certain listed drugs

1 Pharmaceutical benefits that may be supplied without a prescription by an approved pharmacist – pharmaceutical benefits that have certain listed drugs

Endnotes

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

 

 

 (1) This instrument is the National Health (Continued Dispensing) Determination 2022.

 (2) This instrument may also be cited as PB 59 of 2022.

  This instrument is made under subsection 89A(3) of the National Health Act 1953.

 (1) In this instrument:

Act means the National Health Act 1953.

electronic prescription has the meaning given by subsection 5(1) of the Regulations.

increased maximum quantity, for a pharmaceutical item, means a quantity or number of units that has been determined under paragraph 85A(2)(a) of the Act as the maximum quantity or number of units of the pharmaceutical item in the pharmaceutical benefit that may, for a relevant purpose, be directed in a prescription to be supplied on any one occasion.

patient: see subsection 3.01(1).

purposes code has the meaning given by the National Health (Listing of Pharmaceutical Benefits) Instrument 2024.

Regulations means the National Health (Pharmaceutical Benefits) Regulations 2017.

relevant purpose, for a pharmaceutical benefit, means a purpose, mentioned in Part 1 of Schedule 4 of the National Health (Listing of Pharmaceutical Benefits) Instrument 2024 for a purposes code specified in Schedule 1 of that instrument for the pharmaceutical benefit, that includes the phrase “The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient”.

requested supply: see subsection 3.01(1).

 (2) Where an expression that is used in this instrument is defined for the purposes of Part VII of the Act, it has the same meaning in this instrument as it has in that Part. Expressions used in this instrument that are defined in Part VII include the following:

 (a) approved pharmacist;

 (b) pbs prescriber;

 (c) pharmaceutical benefit has a drug;

 (d) pharmaceutical benefit;

 (e) pharmaceutical item;

 (f) schedule equivalent.

  The purpose of this instrument is to determine:

 (a) the pharmaceutical benefits that may be supplied by an approved pharmacist without a prescription; and

 (b) the conditions that must be satisfied when making a supply of those pharmaceutical benefits.

 

  For the purposes of paragraph 89A(3)(a) of the Act, each pharmaceutical benefit that has a drug mentioned in an item in Schedule 1 is determined to be a pharmaceutical benefit that may be supplied by an approved pharmacist without a prescription.

Note: A pharmaceutical benefit has the drug or medicinal preparation referred to in paragraph (a) of the definition pharmaceutical benefit in relation to that benefit – see subsection 84ABA(3).

 

 (1) For the purposes of paragraph 89A(3)(b) of the Act, the conditions specified in this Part are determined to be the conditions that must be satisfied when making a supply (the requested supply) of a pharmaceutical benefit to a person (the patient) requesting the supply without a prescription in accordance with subsection 89A(1) of the Act.

 (2) In this Part:

 (a) a reference to the PBS prescriber is a reference to the PBS prescriber who most recently prescribed the supply of the pharmaceutical benefit to the patient; and

 (b) a reference to “the pharmaceutical benefit” in sections 3.03, 3.05, 3.06 and 3.07 includes a reference to a pharmaceutical benefit that is a Schedule equivalent.

  The approved pharmacist must be satisfied of either or both of the following:

 (a) the PBS prescriber is unable to be contacted;

 (b) the PBS prescriber is unable to provide an electronic prescription.

  The approved pharmacist must be satisfied that:

 (a) the patient has previously been supplied the pharmaceutical benefit on the basis of a prescription from a PBS prescriber; and

 (b) the PBS prescriber prescribed the supply of the pharmaceutical benefit for the patient in at least one of the circumstances determined for that pharmaceutical benefit under paragraph 85(7)(b) of the Act.

Note: The circumstances determined under paragraph 85(7)(b) of the Act relate to pharmaceutical benefits that are relevant pharmaceutical benefits under section 88A of the Act.

  The approved pharmacist must be satisfied that the patient’s therapy is stable.

  The approved pharmacist must be satisfied that:

 (a) the patient has been taking the pharmaceutical benefit regularly for an uninterrupted period; and

 (b) since the start of that period, the PBS prescriber has assessed the patient’s condition and decided that there is a need for ongoing treatment with the pharmaceutical benefit.

Note: See paragraph 3.01(2)(a) for references to the PBS prescriber.

  The approved pharmacist must be satisfied that the patient had a valid prescription under Part VII of the Act for the last supply of the pharmaceutical benefit to the patient before the requested supply.

  The approved pharmacist must be satisfied that the patient was not supplied with the pharmaceutical benefit under subsection 89A(1) of the Act in the 12 months before the requested supply.

  The approved pharmacist must ensure that the patient, or an agent of the patient (other than the approved pharmacist), signs a declaration acknowledging that the patient is being supplied with the pharmaceutical benefit without the presentation of a valid prescription under Part VII of the Act.

 (1) The approved pharmacist must supply a maximum quantity or number of units of the pharmaceutical item in the pharmaceutical benefit determined under paragraph 85A(2)(a) of the Act.

 (2) However, where an increased maximum quantity has been determined for the pharmaceutical item in the pharmaceutical benefit, the approved pharmacist may only supply that increased maximum quantity if the last supply to the patient of the pharmaceutical benefit, or a pharmaceutical benefit that is Schedule equivalent, was on the basis of a prescription written for:

 (a) a relevant purpose for the pharmaceutical benefit; or

 (b) a relevant purpose for a pharmaceutical benefit that is Schedule equivalent to the pharmaceutical benefit.

 (1) The approved pharmacist must, when the pharmaceutical benefit is supplied:

 (a) record the information that the pharmacist used to support the pharmacist’s decision to supply the pharmaceutical benefit; and

 (b) prepare information about the supply to the patient that the pharmacist will send to the PBS prescriber.

 (2) The information that must be recorded and prepared under subsection (1) must include the following:

 (a) a statement that the pharmaceutical benefit supplied is a pharmaceutical benefit covered by Schedule 1;

 (b) a statement that the conditions mentioned in sections 3.02 to 3.05 are satisfied;

 (c) a statement that the approved pharmacist is satisfied that the pharmaceutical benefit needs to be supplied to the patient to facilitate continuity of treatment.

Note: See section 2.01.

 

 

 

Item

Listed drug

1

Abacavir

2

Abacavir with lamivudine

3

Acarbose

4

Alogliptin

5

Alogliptin with metformin

6

Amlodipine

7

Amlodipine with atorvastatin

8

Amlodipine with valsartan

9

Amlodipine with valsartan and hydrochlorothiazide

10

Atazanavir

11

Atazanavir with cobicistat

12

Atenolol

13

Atorvastatin

14

Beclometasone

15

Beclometasone with formoterol

16

Bictegravir with emtricitabine with tenofovir alafenamide

17

Bisoprolol

18

Budesonide

19

Budesonide with formoterol

20

Candesartan

21

Candesartan with hydrochlorothiazide

22

Captopril

23

Carvedilol

24

Chlortalidone

25

Ciclesonide

26

Dapagliflozin

27

Dapagliflozin with metformin

28

Dapagliflozin with sitagliptin

29

Darunavir

30

Darunavir with cobicistat

31

Darunavir with cobicistat, emtricitabine and tenofovir alafenamide

32

Diltiazem

33

Dolutegravir with abacavir and lamivudine

34

Dolutegravir with lamivudine

35

Dolutegravir with rilpivirine

36

Drospirenone

37

Drospirenone with ethinylestradiol

38

Dulaglutide

39

Empagliflozin

40

Empagliflozin with linagliptin

41

Empagliflozin with metformin

42

Emtricitabine with rilpivirine with tenofovir alafenamide

43

Emtricitabine with tenofovir alafenamide

44

Enalapril

45

Enalapril with hydrochlorothiazide

46

Entecavir

47

Eplerenone

48

Eprosartan

49

Eprosartan with hydrochlorothiazide

50

Estetrol with drospirenone

51

Etonogestrel with ethinylestradiol

52

Etravirine

53

Ezetimibe and rosuvastatin

54

Ezetimibe with atorvastatin

55

Ezetimibe with simvastatin

56

Felodipine

57

Fluticasone furoate

58

Fluticasone furoate with vilanterol

59

Fluticasone propionate

60

Fluticasone propionate with formoterol

61

Fluticasone propionate with salmeterol

62

Fluvastatin

63

Formoterol

64

Fosinopril

65

Furosemide

66

Glibenclamide

67

Gliclazide

68

Glimepiride

69

Glipizide

70

Hydrochlorothiazide

71

Hydrochlorothiazide with amiloride

72

Indacaterol

73

Indacaterol with mometasone

74

Indapamide

75

Insulin aspart

76

Insulin aspart with insulin aspart protamine suspension

77

Insulin degludec with insulin aspart

78

Insulin detemir

79

Insulin glargine

80

Insulin glulisine

81

Insulin isophane

82

Insulin lispro

83

Insulin lispro with insulin lispro protamine suspension

84

Insulin neutral

85

Insulin neutral with insulin isophane

86

Irbesartan

87

Irbesartan with hydrochlorothiazide

88

Labetalol

89

Lamivudine

90

Lamivudine with zidovudine

91

Lercanidipine

92

Lercanidipine with enalapril

93

Levonorgestrel

94

Levonorgestrel with ethinylestradiol

95

Linagliptin

96

Linagliptin with metformin

97

Lisinopril

98

Lopinavir with ritonavir

99

Maraviroc

100

Metformin

101

Metoprolol

102

Metoprolol succinate

103

Nebivolol

104

Nevirapine

105

Nifedipine

106

Norethisterone

107

Norethisterone with ethinylestradiol

108

Olmesartan

109

Olmesartan with amlodipine

110

Olmesartan with amlodipine and hydrochlorothiazide

111

Olmesartan with hydrochlorothiazide

112

Perindopril

113

Perindopril with amlodipine

114

Perindopril with indapamide

115

Pioglitazone

116

Pravastatin

117

Propranolol

118

Quinapril

119

Ramipril

120

Ramipril with felodipine

121

Rilpivirine

122

Ritonavir

123

Rosuvastatin

124

Sacubitril with valsartan

125

Salbutamol

126

Salmeterol

127

Saxagliptin

128

Saxagliptin with dapagliflozin

129

Saxagliptin with metformin

130

Semaglutide

131

Simvastatin

132

Sitagliptin

133

Sitagliptin with metformin

134

Sotalol

135

Spironolactone

136

Telmisartan

137

Telmisartan with amlodipine

138

Telmisartan with hydrochlorothiazide

139

Tenofovir

140

Tenofovir alafenamide with emtricitabine, elvitegravir and cobicistat

141

Tenofovir with emtricitabine

142

Tenofovir with emtricitabine and efavirenz

143

Terbutaline

144

Trandolapril

145

Trandolapril with verapamil

146

Valsartan

147

Valsartan with hydrochlorothiazide

148

Verapamil

149

Vildagliptin

150

Vildagliptin with metformin

151

Zidovudine

 

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Abbreviation key—Endnote 2

The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes

The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments

A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the Legislation Act 2003.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.

 

 

ad = added or inserted

orig = original

am = amended

p = page(s)

amdt = amendment

para = paragraph(s)/subparagraph(s)

C[x] = Compilation No. x

/subsubparagraph(s)

ch = Chapter(s)

pres = present

cl = clause(s)

prev = previous

cont. = continued

(prev…) = previously

def = definition(s)

pt = Part(s)

Dict = Dictionary

r = regulation(s)/Court rule(s)

disallowed = disallowed by Parliament

reloc = relocated

div = Division(s)

renum = renumbered

ed = editorial change

rep = repealed

exp = expires/expired or ceases/ceased to have

rs = repealed and substituted

effect

s = section(s)/subsection(s)

gaz = gazette

/rule(s)/subrule(s)/order(s)/suborder(s)

LA = Legislation Act 2003

sch = Schedule(s)

LIA = Legislative Instruments Act 2003

SLI = Select Legislative Instrument

(md) = misdescribed amendment can be given

SR = Statutory Rules

effect

sub ch = SubChapter(s)

(md not incorp) = misdescribed amendment

sub div = Subdivision(s)

cannot be given effect

sub pt = Subpart(s)

mod = modified/modification

underlining = whole or part not

No. = Number(s)

commenced or to be commenced

Ord = Ordinance

 

 

 

Name

Registration

Commencement

Application, saving and transitional provisions

National Health (Continued Dispensing) Determination 2022 (PB 59 of 2022)

30 June 2022 (F2022L00884)

1 July 2022 (s 1.02(1) item 1)

 

National Health (Continued Dispensing) Amendment Determination 2022 (No. 1) (PB 88 of 2022)

30 Sept 2022 (F2022L01306)

1 Oct 2022 (s 2(1) item 1)

National Health (Continued Dispensing) Amendment Determination 2023 (No. 1) (PB 70 of 2023)

31 July 2023 (F2023L01045)

1 Aug 2023 (s 2(1) item 1)

National Health (Continued Dispensing) Amendment Determination 2023 (No. 2) (PB 83 of 2023)

31 Aug 2023 (F2023L01156)

1 Sept 2023 (s 2(1) item 1)

National Health (Continued Dispensing) Amendment Determination 2023 (No. 3) (PB 115 of 2023)

30 Nov 2023 (F2023L01576)

1 Dec 2023 (s 2(1) item 1)

National Health (Continued Dispensing) Amendment Determination 2024 (No. 1) (PB 50 of 2024)

30 Apr 2024 (F2024L00507)

1 May 2024 (s 2(1) item 1)

National Health (Continued Dispensing) Amendment Determination 2024 (No. 2) (PB 98 of 2024)

30 Sept 2024 (F2024L01242)

1 Oct 2024 (s 2(1) item 1)

National Health (Continued Dispensing) Amendment Determination 2024 (No. 3) (PB 114 of 2024)

31 Oct 2024 (F2024L01393)

1 Nov 2024 (s 2(1) item 1)

National Health (Continued Dispensing) Amendment Determination 2024 (No. 4) (PB 134 of 2024)

29 Nov 2024 (F2024L01544)

1 Dec 2024 (s 2(1) item 1)

National Health (Continued Dispensing) Amendment Determination 2025 (No. 1) (PB 16 of 2025)

28 Feb 2025 (F2025L00218)

1 Mar 2025 (s 2(1) item 1)

National Health (Continued Dispensing) Amendment Determination 2025 (No. 2) (PB 43 of 2025)

30 Apr 2025 (F2025L00537)

1 May 2025 (s 2(1) item 1)

National Health (Continued Dispensing) Amendment Determination 2025 (No. 3) (PB 87 of 2025)

31 July 2025 (F2025L00880)

1 Aug 2025 (s 2(1) item 1)

National Health (Continued Dispensing) Amendment Determination 2025 (No. 4) (PB 108 of 2025)

30 Sept 2025 (F2025L01214)

1 Oct 2025 (s 2(1) item 1)

National Health (Continued Dispensing) Amendment Determination 2025 (No. 5) (PB 125 of 2025)

31 Oct 2025 (F2025L01317)

1 Nov 2025 (s 2(1) item 1)

 

 

Provision affected

How affected

Part 1

 

s 1.02...................

rep LA s 48D

s 1.04...................

rep LA s 48C

s 1.05...................

am F2023L01576; F2024L01393

Part 2

 

s 2.01...................

rs F2024L01393

Part 3

 

s 3.09...................

rs F2023L01576

Part 4...................

rep F2024L01393

Schedule 1

 

Schedule 1 heading..........

am F2024L01393

Schedule 1................

am F2024L01393

s 1.....................

am F2022L01306; F2023L01045; F2023L01156; F2024L00507; F2024L01242; F2024L01393; F2024L01544; F2025L00218; F2025L00537; F2025L00880; F2025L01214; F2025L01317

Schedule 2................

rep LA s 48C